Merck & Co. reported Q3 2025 revenue of $17.3 billion, marking a 4% increase from the previous year. The pharmaceutical giant has raised its full-year sales forecast to between $64.5 billion and $65 billion, alongside an increased non-GAAP EPS projection of $8.93 to $8.98. This growth is attributed to strong sales of KEYTRUDA and WINREVAIR, as well as strategic initiatives including the FDA approval of KEYTRUDA QLEX and the acquisition of Verona Pharma, enhancing its product pipeline.